Cargando…
A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dustri-Verlag Dr. Karl Feistle
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715206/ https://www.ncbi.nlm.nih.gov/pubmed/29318105 http://dx.doi.org/10.5414/CNCS109165 |